CEO of cancer company CEL-SCI Corporation (NYSE: CVM). Make the world a better place, make a difference, and take care of your family. Only my personal opinion!
Washington, DC
Joined May 2020
- Tweets311
- Following225
- Followers2.2K
- Likes200
Most investments begin in discomfort. That is what a famous investor wrote. oaktreecapital.com/insights/…. We are at that stage because until a few days ago there was no clear regulatory path to market. Now there is. Look at our clinical data. Think longer term for huge returns. $CVM
$CVM Thank you for the go-ahead from FDA for the confirmatory trial. We already know how the selected patients did in the completed study. 73% survival with Multikine vs 45% without Multikine. We can help a lot of patients. I believe! So I bought more stock.
$CVM At CEL-SCI we are looking forward to a month filled with several very important meetings designed to bring our cancer therapy Multikine to market. We will keep you updated on our progress.
$CVM If I look at our history, things have always taken longer than hoped for, but we were always successful in the end. These results make it clear that our Multikine can really help cancer patients. That is the key, helping cancer patients.
CEL-SCI’s #Multikine Phase 3 Cancer Study Shows 43% Survival Extension #ECHNO $CVM - businesswire.com/news/home/2…
$CVM If I was a head and neck cancer patient, I surely would want to get the chance to have my expected death rate reduced from 54 to 22%. Nothing else has worked for these patients in ages.
#Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment $CVM - businesswire.com/news/home/2…
$CVM We persisted when experts told us that cancer immunotherapy would not work, that head & neck cancer was an impossible to treat disease, yet we have an almost 4 yr survival benefit for patients receiving our Multikine plus surgery and radiation.
This Post is from a suspended account. Learn more
$CVM We had well over 100 interested physicians review the results of our Phase 3 head and neck cancer study with us today at ASCO 2022. Very positive feed back. Thank you Dr. Talor.
$CVM I am so proud of our team. An almost 4 year survival benefit in head and neck cancer with no toxicity added. That is why we believe!
$CVM When you finally learn the details of the huge data set for the Multikine Phase 3 study, think of how this might help cancer patients. That is what will drive things from here on. The rest is background noise.
CEL-SCI $CVM Announces Acceptance of Abstracts to ASCO 2022 #ASCO22 #Multikine - businesswire.com/news/home/2…
$CVM It is a sad statement for our society when a Company has to defend itself from stock manipulators after creating a novel cancer drug that increases survival from 48 to 62% at 5 yrs with no safety issues, beating all statistics. Unmet medical need, orphan drug status.
CEL-SCI $CVM Corporation Issues Letter to Shareholders #Multikine | Business Wire businesswire.com/news/home/2…
$CVM We showed survival data exceeding all primary endpoints for 1 of 2 treatment arms with no safety issues. On the call yesterday we showed that this analysis was pre-specified in the protocol and conducted BEFORE unblinding, confirmed by the biostatistician, per the FDA rules
$CVM FDA works on the basis of data and clinical benefit. They will decide whether a statistically significant 5 yr. survival difference between 48 and 62% for a terrible unmet need is approvable. Does it help these patients? We believe that it does.
$CVM I tip my hat in respect of the short sellers ability to make the great survival benefit with no safety issues look bad. Unreal. This reminds me of when we won the arbitration against Inventiv, a huge win, and the stock declined. I bought over 300,000 shares at $0.84.
$CVM Cancer drugs usually work in only a small percentage of people and have a lot of safety problems. They still get approved. We think that we have done much better than that. IS IT HELPING THE PATIENTS?
$CVM Such amount of misinformation. Great data and we believe very approvable. The analysis we did was included in the protocol and the Statistical Analysis Plan and is therefore acceptable to FDA. The group is 1 of 2 and represents over 150,000 patients.
The $CVM Phase 3 study shows great overall survival benefit (ITT) of 14.1% (62.7% vs 48.6%) at 5 yrs. No safety issues. Outstanding p=0.0236, Hazard ratio=0.68. Survival increases over time. We plan to seek FDA approval for this unmet need.
CEL-SCI’s $CVM Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study #Multikine | Business Wire businesswire.com/news/home/2…
We $CVM fight for a better way to treat cancer every day. Be a part of our team and help us with your votes.
$CVM Shareholders, please vote. Too many of you have told me that your broker has not sent you your proxy or that you simply have not voted. Please ask for the proxy from your broker or call 877-870-8565 for help. We need your support every day.
My team and I have invested a life time and huge amounts of money into $CVM trying to create a super safe cancer drug that will do something that has not ever been done. Final data almost here. Why such hate from some? Wishing a better way of treating cancer ill? So wrong!!!
$CVM For those manipulative people who claim that we are trying to delay the final analysis of our huge cancer study. Everything is messed up thanks to COVID. Despite all of that our CROs have met one milestone after another while maintaining quality. cnbc.com/2021/06/13/home-dep…
